financetom
Business
financetom
/
Business
/
Bombay High Court puts on hold CCI probe of debt trustee units of SBI, Axis, IDBI Bank
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Bombay High Court puts on hold CCI probe of debt trustee units of SBI, Axis, IDBI Bank
Apr 11, 2022 10:14 AM

An Indian court on Monday put on hold an antitrust investigation into trustee units of State Bank of India, Axis Bank and IDBI Bank for suspected collusion on fees, saying the market regulator would first look into the case.

Indian regulations mandate that companies raising debt appoint a so-called "debenture trustee" to protect the interests of investors. The trustees charge a fee from the companies issuing the debt and make due-diligence checks on them.

Reuters reported last week the Competition Commission of India (CCI) had ordered an investigation into debt trustee units of the three banks and a group representing them had gone to court seeking to quash the probe.

Hearing the plea, the judges in the High Court in Mumbai said the market regulator SEBI - which is also investigating the matter - should complete its probe within 60 days, and until then the antitrust investigation will remain on hold.

Also Read

| Sebi clarifies on validity period of omnibus approval for related party transactions

SEBI is the sectoral regulator and should first review the allegations, the trustees had argued in the court.

The three under investigation - SBICAP Trustee Company, Axis Trustee and IDBI Trusteeship - are among the leaders in the business in India overseeing hundreds of billions of dollars by rendering trustee services for not just debt securities, but also real estate and other investment funds.

First Published:Apr 11, 2022 7:14 PM IST

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
Zimmer Biomet Facing Patent Infringement Lawsuit From Treace Medical
Zimmer Biomet Facing Patent Infringement Lawsuit From Treace Medical
Jun 5, 2025
02:11 PM EDT, 06/05/2025 (MT Newswires) -- Zimmer Biomet ( ZBH ) is facing a patent infringement lawsuit from Treace Medical Concepts ( TMCI ) , which claims infringement of four patents. According to a statement from Treace on Thursday, Zimmer Biomet ( ZBH ) and its subsidiary Paragon 28 were in violation of patents covering its Lapiplasty technology. The...
Circle Surges To $69 In NYSE Debut, Raising $1.1B As Investors Bet On Stablecoins Going Mainstream
Circle Surges To $69 In NYSE Debut, Raising $1.1B As Investors Bet On Stablecoins Going Mainstream
Jun 5, 2025
Circle (CRYPTO: USDC) made a powerful entrance onto the New York Stock Exchange on Thursday, with shares of the stablecoin issuer opening at $69, more than double its $31 IPO price. The company raised approximately $1.1 billion through the sale of 34 million shares, securing a valuation of $6.9 billion and marking a major milestone after a previously unsuccessful public...
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs
US Health Secretary Kennedy looks to fast-tracking approvals for rare disease drugs
Jun 5, 2025
By Sneha S K and Sriparna Roy (Reuters) -Health and Human Services Secretary Robert F. Kennedy Jr. said on Thursday that the U.S. drugs regulator would look for ways to fast-track approval for rare disease treatments and remove obstacles to their path to market. Kennedy made the comments at a U.S. Food and Drug Administration meeting to discuss cell and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved